A5029618892- Cancer Genomics and Diagnostics
- Cancer Cells and Metastasis
- Hippo pathway signaling and YAP/TAZ
- Cancer Immunotherapy and Biomarkers
- Cellular Mechanics and Interactions
- Cell death mechanisms and regulation
- Single-cell and spatial transcriptomics
University of California, San Francisco
2024-2025
Non-small cell lung cancers (NSCLC) harboring common mutations in EGFR and KRAS characteristically respond transiently to targeted therapies against those mutations, but invariably, tumors recur progress. Resistance often emerges through the therapeutic target or activation of alternative signaling pathways. Mechanisms acute tumor resistance initial (EGFRi) G12C (G12Ci) pathway inhibition remain poorly understood. Our study reveals that response EGFR/RAS/RAF-pathway is spatial culture...
Non-small cell lung cancers (NSCLC) harboring common mutations in EGFR and KRAS characteristically respond transiently to targeted therapies against those mutations, but invariably, tumors recur progress. Resistance often emerges through the therapeutic target or activation of alternative signaling pathways. Mechanisms acute tumor resistance initial (EGFRi) G12C (G12Ci) pathway inhibition remain poorly understood. Our study reveals that response EGFR/RAS/RAF-pathway is spatial culture...
Metastasis is the leading cause of cancer-related deaths. It unclear how intratumor heterogeneity (ITH) contributes to metastasis and metastatic cells adapt distant tissue environments. The study these adaptations challenged by limited access patient material a lack experimental models that appropriately recapitulate ITH. To investigate cell contribution ITH metastasis, we analyzed single-cell transcriptomes matched primary tumors metastases from patient-derived xenograft breast cancer. We...
Metastasis is the leading cause of cancer-related deaths, but metastasis research challenged by limited access to patient material and a lack experimental models that appropriately recapitulate tumor heterogeneity. Here, we analyzed single-cell transcriptomes matched primary from patient-derived xenograft breast cancer, demonstrating metastatic cells show profound transcriptional differences across heterogeneous tumors. While upregulated several metabolic genes, displayed motility phenotype...
Non-small cell lung cancers (NSCLC) harboring common mutations in EGFR and KRAS characteristically respond transiently to targeted therapies against those mutations, but invariably, tumors recur progress. Resistance often emerges through the therapeutic target or activation of alternative signaling pathways. Mechanisms acute tumor resistance initial (EGFRi) KRASG12C (G12Ci) pathway inhibition remain poorly understood. Our study reveals that response EGFR/RAS/RAF-pathway is spatial culture...